HLB group stocks closed mixed in the regular session on the 2nd. While only HLB and HLB Therapeutics stayed in positive territory, a considerable number of affiliates, including HLB Pharmaceutical, ended the session weaker, highlighting a clear divergence within the group's shares.

■ Gainers: HLB and HLB Therapeutics

HLB (028300) closed at 40,650 won, up 0.24% from the previous day, showing modest strength. HLB Therapeutics (115450) also finished at 2,495 won, up 1.62%, staying in positive territory alongside HLB.

■ Losers: HLB Pharmaceutical Down 9.86%

In contrast, HLB Pharmaceutical (047920) closed at 10,050 won, down 9.86%, recording the biggest decline among the group's stocks. HLB Biostep (278650) ended trading down 5.56% at 2,885 won, HLB Global (003580) fell 3.91% to 1,791 won, and HLB Life Science (067630) dropped 3.76% to 3,575 won. HLB Innovation (024850) closed down 0.30% at 16,450 won, while HLB Panagene (046210) fell 0.88% to 1,239 won.

■ Volatility Widens After 'Lytens' FDA Approval

HLB group stocks have recently drawn market attention with sharp price swings. In particular, on the 28th of last month, news of the U.S. Food and Drug Administration (FDA) approving the bile duct cancer targeted therapy 'Lytens' sent major affiliates' shares to their upper daily limits en masse. Since then, the stocks have shown differentiated movements.

■ Watch Point: October 6, First Trading Day After the Holiday

Attention is now focused on how HLB group stocks will move on the 6th, the first trading day after the National Foundation Day holiday. How investor sentiment forms over the holiday, and whether the recently expanded volatility will continue, are also key points to watch.

However, given the sharp short-term price swings, investors need to closely review related disclosures and company-specific issues.

[※ This article is for investment reference purposes only; investment decisions and responsibilities rest with the investor.]